|
Median age | 81 years (minimum 70, maximum 88) |
|
Sex | 9 men |
5 women |
|
Indication oral anticoagulant | Atrial fibrillation (n = 12) |
Thrombosis dialysis catheter (n = 1) |
Arterial embolisms (n = 1) |
|
VKA | Warfarin (n = 12) |
Fenprocoumon (n = 2) |
|
Target INR | INR 2–3 (n = 14) |
|
Catheter | Arrow cannon II plus catheter (teleflex medical) 23 cm (n = 9) |
BioFloTM DuraMax (AngioDynamics Navilyst Medical) (n =2) |
Others (n = 3) |
All dual lumen catheters |
|
Catheter lock | Heparin natrium (5000 IU/ml, n = 11) (B. Braun) |
Taurolock-Hep500TM (contains 500 IU/ml UFH and citrate 4%) (n = 2) (TauroPharm GmbH) |
Citra-LockTM (citrate 4%, n = 1) (Dirinco N.V.) |
|
Dialysis | Hemodialysis (n = 4) |
Hemodiafiltration predilution (n = 1) |
Hemodiafiltration postdilution (n = 5) |
Hemodiafiltration mixed (n = 4) |
All via Fresenius 5008 or 5008 S monitors |
|
Dialysis filter | FX CorDiax 80TM (Fresenius) (n =2) |
FX CorDiax 1000TM (Fresenius) (n = 9) |
Nephral 400 STTM (Baxter) (n = 2) |
Polyflux 170 H TM (Gambro) (n = 1) |
|
Anticoagulation during dialysis | Unfractionated heparin (UFH) (n = 14) |
Mean heparin dose at start (in IV bolus) | 31.9 IU/kg |
Mean heparin dose during dialysis (in continuous infusion) | 22.5 IU/kg |
|